Related to BD Partners with Lab21 to Develop Aspergillus Assay for BD MAX Real-Time PCR Platform

• ExonHit Launches Alzheimer Diagnostic for Research Use
  
• Interleukin Genetics Launches Bone Health Genetic Test
  
• Exiqon to Divest Its U.S. CLIA Laboratory Operation
  
• Ferrer InCode to Market BioTheranostics’ Cancer Classification Assay in Four Countries
  
• KaloBios Obtains $35M Up Front from Sanofi Pasteur for Clinical Antibody Candidate against Pseudomonas Aeruginosa
  
• Celera Grants License Covering KIF6 Testing to UCSF
  
• Life Technologies to Pick Up AcroMetrix for Molecular Diagnostics
  
• Rosetta Genomics to Receive $4.5M in a Registered Direct Offering
  
• Abbott Wins CE Mark for Epithelial Ovarian Cancer Diagnostic
  
• GlobeImmune Raises $17.5M in Series E Financing
  
• Llama Antibodies Used to Detect Botulinum Neurotoxins in Liquids
  
• Assay that Examines Hundreds of Proteins Simultaneously Invented
  
• Asuragen Allies with Clinical Centers to Validate miRNA Pancreatic Cancer Test
  
• Agilent Sells In Vitro Diagnostic Segment Hycor to Linden
  
• Optimer Reports Positive Phase III Data for Antibiotic against C. Difficile
  
• Zetiq Reports Clinical Validation of Platform for Bladder Cancer Diagnosis
  
• Takara Bio Negotiates License to Roche Diagnostics’ Melting Curve Analysis and SYBR Green Techniques
  
• NextGen to Develop Biomarker Assays for Takeda’s Research
  
• Qiagen to Distribute Celera’s ResPlex II Multiplex Assay for Respiratory Pathogens
  
• Bar Harbor BioTechnology Gains PCR and Real-Time PCR Patents from Life Technologies